1
|
El Malki H, Moutawakkil SG, El-Ammari A, Ragala MEA, El Hilaly J, El Gnaoui S, El Houari F, El Rhazi K, Zarrouq B. Psychometric properties of the cannabis abuse screening test (CAST) in a sample of Moroccans with cannabis use. Addict Sci Clin Pract 2024; 19:24. [PMID: 38570799 PMCID: PMC10988931 DOI: 10.1186/s13722-024-00459-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Accepted: 03/27/2024] [Indexed: 04/05/2024] Open
Abstract
BACKGROUND The Cannabis Abuse Screening Test (CAST) is a widely used screening tool for identifying patterns of cannabis use that have negative health or social consequences for both the user and others involved. This brief screening instrument has been translated into multiple languages, and several studies examining its psychometric properties have been published. However, studies on the factorial validity and psychometric properties of a Moroccan version of the CAST are not yet available. The objective of this study is to validate the CAST, translated, and adapted to the Moroccan Arabic dialect among persons with cannabis use. METHODS A total of 370 participants from an addictology center in Fez City, were selected over two phases to form the study sample. First, in phase I, exploratory factor analysis was employed to evaluate the factor structure in the pilot sample (n1 = 150). Subsequently, in the second phase (Phase II), confirmatory factor analysis was utilized to confirm this structure in the validation sample (n2 = 220). All statistical analyses were carried out using the R program. RESULTS The CFA unveiled a three-factor structure that showed a good overall fit (χ2/df = 2.23, RMSEA = 0.07, SRMR = 0.02, CFI = 0.99, NFI = 0.98) and satisfactory local parameters (standardized factor loadings between 0.72 and 0.88). The model demonstrates satisfactory reliability and convergent validity, as evidenced by the acceptable values of composite reliability (CR) (0.76-0.88) and average variance extracted (AVE) (0.62-0.78), respectively. The square roots of the AVE exceeded the correlations of the factor pairs, and the heterotrait-monotrait (HTMT) ratio of the correlation values was below 0.85, indicating acceptable discriminant validity. CONCLUSION The reliability, convergent validity, and discriminant validity tests all demonstrated that the Moroccan version of the CAST performed well and can be considered a valid tool for screening of problematic cannabis use.
Collapse
Affiliation(s)
- Hicham El Malki
- Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine, Pharmacy, and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
| | - Salma Ghofrane Moutawakkil
- Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine, Pharmacy, and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, Morocco
| | - Abdelfettah El-Ammari
- Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine, Pharmacy, and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, Morocco
| | - Mohammed El Amine Ragala
- Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine, Pharmacy, and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, Morocco
- Department of Biology-Geology, Teachers Training College (Ecole Normale Superieure), Sidi Mohamed Ben Abdellah University, Fez, Morocco
| | - Jaouad El Hilaly
- R.N.E Laboratory, Multidisciplinary Faculty of Taza, Sidi Mohamed Ben Abdellah University, Fez, Morocco
- Laboratory of Pedagogical and Didactic Engineering of Sciences and Mathematics, Regional Center of Education and Training (CRMEF), Fez, Morocco
| | | | | | - Karima El Rhazi
- Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine, Pharmacy, and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, Morocco
| | - Btissame Zarrouq
- Laboratory of Epidemiology and Research in Health Sciences, Faculty of Medicine, Pharmacy, and Dental Medicine, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
- Department of Biology-Geology, Teachers Training College (Ecole Normale Superieure), Sidi Mohamed Ben Abdellah University, Fez, Morocco.
| |
Collapse
|
2
|
Hamieh N, Airagnes G, Descatha A, Goldberg M, Limosin F, Roquelaure Y, Lemogne C, Zins M, Matta J. Atypical working hours are associated with tobacco, cannabis and alcohol use: longitudinal analyses from the CONSTANCES cohort. BMC Public Health 2022; 22:1834. [PMID: 36175874 PMCID: PMC9523930 DOI: 10.1186/s12889-022-14246-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 09/19/2022] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND This study examined prospective associations between atypical working hours with subsequent tobacco, cannabis and alcohol use as well as sugar and fat consumption. METHODS In the French population-based CONSTANCES cohort, 47,288 men and 53,324 women currently employed included between 2012 and 2017 were annually followed for tobacco and cannabis use. Among them, 35,647 men and 39,767 women included between 2012 and 2016 were also followed for alcohol and sugar and fat consumption. Three indicators of atypical working hours were self-reported at baseline: working at night, weekend work and non-fixed working hours. Generalized linear models computed odds of substance use and sugar and fat consumption at follow-up according to atypical working hours at baseline while adjusting for sociodemographic factors, depression and baseline substance use when appropriate. RESULTS Working at night was associated with decreased smoking cessation and increased relapse in women [odds ratios (ORs) of 0.81 and 1.25], increased cannabis use in men [ORs from 1.46 to 1.54] and increased alcohol use [ORs from 1.12 to 1.14] in both men and women. Weekend work was associated with decreased smoking cessation in women [ORs from 0.89 to 0.90] and increased alcohol use in both men and women [ORs from 1.09 to 1.14]. Non-fixed hours were associated with decreased smoking cessation in women and increased relapse in men [ORs of 0.89 and 1.13] and increased alcohol use in both men and women [ORs from 1.12 to 1.19]. Overall, atypical working hours were associated with decreased sugar and fat consumption. CONCLUSIONS The potential role of atypical working hours on substance use should be considered by public health policy makers and clinicians in information and prevention strategies.
Collapse
Affiliation(s)
- Nadine Hamieh
- grid.7429.80000000121866389INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France
| | - Guillaume Airagnes
- grid.7429.80000000121866389INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France ,grid.508487.60000 0004 7885 7602Université Paris Cité, Faculty of Health, School of Medicine, Université Paris Cité, F-75006 Paris, France ,grid.414093.b0000 0001 2183 5849AP-HP.Centre-Université de Paris, DMU Psychiatrie et Addictologie, Centre Ambulatoire d’Addictologie, Hôpital européen Georges-Pompidou, F-75015 Paris, France
| | - Alexis Descatha
- grid.411147.60000 0004 0472 0283Poison Control Center, Academic Hospital CHU Angers, F-49000 Angers, France ,grid.7252.20000 0001 2248 3363Univ Angers, Centre Hospitalier Universitaire CHU Angers, Université de Rennes, INSERM, École des hautes études en santé publique, Institut de recherche en santé, environnement et travail Irset UMR_S 1085, F-49000 Angers, France ,grid.512756.20000 0004 0370 4759Department of Occupational Medicine, Epidemiology and Prevention, Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, Hempstead, USA
| | - Marcel Goldberg
- grid.7429.80000000121866389INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France ,grid.508487.60000 0004 7885 7602Université Paris Cité, Faculty of Health, School of Medicine, Université Paris Cité, F-75006 Paris, France
| | - Frédéric Limosin
- grid.512035.0Université Paris Cité, INSERM U1266, Institut de Psychiatrie et Neuroscience de Paris, F-75014 Paris, France ,grid.413885.30000 0000 9731 7223AP-HP.Centre-Université de Paris, DMU Psychiatrie et Addictologie, Service de psychiatrie et d’addictologie de l’adulte et du sujet âgé, Hôpital Corentin-Celton, F-912130 Issy-les-Moulineaux, France
| | - Yves Roquelaure
- grid.7252.20000 0001 2248 3363Univ Angers, Centre Hospitalier Universitaire CHU Angers, Université de Rennes, INSERM, École des hautes études en santé publique, Institut de recherche en santé, environnement et travail Irset UMR_S 1085, F-49000 Angers, France ,grid.7252.20000 0001 2248 3363University of Angers, Centre Hospitalier Universitaire d’Angers, Université de Rennes, Centre de consultations de pathologie professionnelle et santé au travail, F-49000 Angers, France
| | - Cédric Lemogne
- grid.512035.0Université Paris Cité, INSERM U1266, Institut de Psychiatrie et Neuroscience de Paris, F-75014 Paris, France ,grid.411394.a0000 0001 2191 1995AP-HP.Centre-Université de Paris, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l’adulte, Hôpital Hôtel-Dieu, F-75004 Paris, France
| | - Marie Zins
- grid.7429.80000000121866389INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France ,grid.508487.60000 0004 7885 7602Université Paris Cité, Faculty of Health, School of Medicine, Université Paris Cité, F-75006 Paris, France
| | - Joane Matta
- grid.7429.80000000121866389INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France
| |
Collapse
|
3
|
Maatoug R, Bihan K, Duriez P, Podevin P, Silveira-Reis-Brito L, Benyamina A, Valero-Cabré A, Millet B. Non-invasive and invasive brain stimulation in alcohol use disorders: A critical review of selected human evidence and methodological considerations to guide future research. Compr Psychiatry 2021; 109:152257. [PMID: 34246194 DOI: 10.1016/j.comppsych.2021.152257] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Revised: 06/17/2021] [Accepted: 06/21/2021] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Alcohol use disorder (AUD) ranks among the leading causes of decrements in disability-adjusted life-years. Long-term exposure to alcohol leads to an imbalance of activity between frontal cortical systems and the striatum, thereby enhancing impulsive behaviours and weakening inhibitory control. Alternative therapeutic approaches such as non-invasive and invasive brain stimulation have gained some momentum in the field of addictology by capitalizing on their ability to target specific anatomical structures and correct abnormalities in dysfunctional brain circuits. MATERIALS AND METHODS The current review, covers original peer-reviewed published research on the use of brain stimulation methods for the rehabilitation of AUD. A broad and systematic search was carried out on four electronic databases: NCBI PubMed, Web of Science, Handbooks and the Cochrane Library. Any original article in English or French language, without restrictions of patient age or gender, article type and publication outlet, were included in the final pool of selected studies. RESULTS The outcomes of this systematic review suggest that the dorsolateral prefrontral cortex (DLPFC) is a promising target for treating AUD with high frequency repetitive transcranial magnetic stimulation. Such effect would reduce feelings of craving by enhancing cognitive control and modulating striatal function. Existing literature also supports the notion that changes of DLPFC activity driven by transcranial direct current stimulation, could decrease alcohol craving and consumption. However, to date, no major differences have been found between the efficacy of these two non-invasive brain-stimulation approaches, which require further confirmation. In contrast, beneficial stronger evidence supports an impact of deep brain stimulation reducing craving and improving quality of life in AUD, effects that would be mediated by an impact on the nucleus accumbens, a central structure of the brain's reward circuitry. Overall, neurostimulation shows promise contributing to the treatment of AUD. Nonetheless, progress has been limited by a number of factors such as the low number of controlled randomized trials, small sample sizes, variety of stimulation parameters precluding comparability and incomplete or questionable sham-conditions. Additionally, a lack of data concerning clinical impact on the severity of AUD or craving and the short follow up periods precluding and accurate estimation of effect duration after discontinuing the treatment, has also limited the clinical relevance of final outcomes. CONCLUSION Brain stimulation remains a promising approach to contribute to AUD therapy, co-adjuvant of more conventional procedures. However, a stronger therapeutic rational based on solid physio-pathological evidence and accurate estimates of efficacy, are still required to achieve further therapeutic success and expand clinical use.
Collapse
Affiliation(s)
- R Maatoug
- Sorbonne Université, AP-HP, Service de psychiatrie adulte de la Pitié-Salpêtrière, Institut du Cerveau, ICM, F-75013 Paris, France.
| | - K Bihan
- Regional pharmacovigilance center, department of pharmacology, Pitié-Salpêtrière hospital, 47/83, boulevard de l'Hôpital, 75013 Paris, France
| | - P Duriez
- Institute of Psychiatry and Neurosciences of Paris, Unité Mixte de Recherche en Santé (UMRS) 1266 Institut National de la Santé et de la Recherche Médicale (INSERM), University Paris Descartes, Paris, France; Clinique des Maladies Mentales et de l'Encéphale, Groupement Hospitalier Universitaire (GHU) Paris Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France
| | - P Podevin
- Sorbonne Université, AP-HP, Service de psychiatrie adulte de la Pitié-Salpêtrière, Institut du Cerveau, ICM, F-75013 Paris, France
| | - L Silveira-Reis-Brito
- Sorbonne Université, AP-HP, Service de psychiatrie adulte de la Pitié-Salpêtrière, Institut du Cerveau, ICM, F-75013 Paris, France; Rede mater dei de saúde, Brazil
| | - A Benyamina
- Dispositif Territorial de Recherche et de Formation (DTRF) Paris Sud, 94275 Le Kremlin-Bicêtre, France; Département de psychiatrie et d'addictologie, Hôpital Paul Brousse, Hôpitaux Universitaires Paris Sud, Assistance Publique-Hôpitaux de Paris, 94800 Villejuif, France
| | - A Valero-Cabré
- Institut du Cerveau et de la Moelle Epinière (ICM), CNRS UMR 7225, INSERM U 1127 and Sorbonne Université, Paris, France; Laboratory for Cerebral Dynamics Plasticity and Rehabilitation, Boston University, School of Medicine, Boston, MA, USA; Cognitive Neuroscience and Information Technology Research Program, Open University of Catalonia (UOC), Barcelona, Spain
| | - B Millet
- Sorbonne Université, AP-HP, Service de psychiatrie adulte de la Pitié-Salpêtrière, Institut du Cerveau, ICM, F-75013 Paris, France
| |
Collapse
|
4
|
Lenglard F, Berger-Vergiat A, Ragonnet D, Duvernay N, Lack P, Poulet E, Zoulim F, Chappuy M. [Feedback from two French addiction centers and national survey on the intranasal naloxone (Nalscue ®) in the prevention of opioid overdoses]. Therapie 2019; 74:477-486. [PMID: 30792078 DOI: 10.1016/j.therap.2019.01.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Revised: 12/18/2018] [Accepted: 01/17/2019] [Indexed: 01/01/2023]
Abstract
OBJECTIVE France has temporarily authorized addictology centers to use a form of intranasal naloxone (Nalscue®) to prevent opioid overdoses. The objectives of this work are to present both the characteristics of the patients included in this device in two hospitals centers and the results of the national survey on addiction center's contribution to this new risk reduction tool. METHODS Patient data are those requested under Nalscue® study (inclusion period July 2016 to January 2018). The survey is an online questionnaire distributed to all addiction centers with an email address. RESULTS Over this period, in the two addiction centers, 370 kits (35% of the national total) were distributed to 330 patients including 312 opioid users. Of these users, 15% report injecting and 85% are poly-consumers. In 14% of the cases, a patient's relative was formed to administrate the Nalscue®. Forty kits (30 given away, 6 lost, 4 administered) were renewed to 35 users. Of the 462 addiction centers contacted, 82 (18%) responded. Among 76 structures specialized in opioid addictions, two did not feel concerned and one had no knowledge of the antidote. Fifty-five structures were formed by the pharmaceutical firm. Nine hundred forty-seven patients (58% of the total) were included by 37 centers. Forty-four centers ordered 2458 kits and dispensed 1116 (including kits given out of study). Thirteen structures reported use of Nalscue®. CONCLUSION The interest of intranasal naloxone is no longer to be demonstrated in a context of opioid overdose, but the preauthorized framework did not allow a major diffusion of the antidote within the population most at risk. Let us hope that the availability in pharmacy can promote its distribution and thus reduce the number of deaths.
Collapse
Affiliation(s)
- Flavy Lenglard
- Institut des sciences pharmaceutiques et biologiques de Lyon, 69008 Lyon, France; Service pharmaceutique, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Aurélie Berger-Vergiat
- Service d'addictologie, centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Delphine Ragonnet
- Service d'addictologie, centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Nathalie Duvernay
- Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France
| | - Philippe Lack
- Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France
| | - Emmanuel Poulet
- Service de psychiatrie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France
| | - Fabien Zoulim
- Service d'hépatologie et gastro-entérologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France
| | - Mathieu Chappuy
- Service pharmaceutique, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France; Service d'addictologie, centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Centre, hospices civils de Lyon, 69003 Lyon, France; Centre de soins, d'accompagnement et de prévention en addictologie, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France; Service pharmaceutique, groupement hospitalier Nord, hospices civils de Lyon, 69004 Lyon, France.
| |
Collapse
|
5
|
Lang JP, Jurado N, Herdt C, Sauvanaud F, Lalanne Tongio L. [Education care in patients with psychiatric disorders in France: Psychoeducation or therapeutic patient education?]. Rev Epidemiol Sante Publique 2018; 67:59-64. [PMID: 30458970 DOI: 10.1016/j.respe.2018.10.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 06/22/2018] [Accepted: 10/06/2018] [Indexed: 11/26/2022] Open
Abstract
CONTEXT Psychoeducation and therapeutic patient education can be effectively included in treatments for patients with psychiatric disorders. These two effective educational therapies have the common purpose of improving disorder-related morbidity, compliance with treatment and patients' quality of life. While they have different methods of application, both teach patients to play an active role in their own care. However, it is still critical to combine them for care of patients with psychiatric and addiction disorders in a manner that allows for specificity. To do this, the differences between psychoeducation and therapeutic patient education must be considered, and their potential for the management of patients with psychiatric and addiction disorders must be determined. METHODS In our article, we review the literature concerning therapeutic education programs for patients and discuss the literature based on the experiences of psychiatrists trained in these therapies. RESULTS Despite rather nonrestrictive guidelines, and after reviewing numerous studies, we found that psychoeducation seems to be rarely used in psychiatry. The use of therapeutic patient education programs for psychiatric patients has doubled in four years but still accounts for less than 4% of validated programs in France. Only 154 programs were developed in 1175 public psychiatric facilities in 2016. Therapeutic patient education has a legal framework and recommendations, which make it suitable for inclusion in care and in the training of care providers. The rigor in the development of therapeutic patient education programs and the requirement for training and financial support reinforce the need for their establishment in healthcare institutions. As such, they could help to modify professional practices and the culture of care in mental health fields. CONCLUSION There is a place for therapeutic patient education in psychiatry as it provides a real benefit for patients. It could modify care practices and costs, and is suitable for patients with psychiatric or addiction disorders by helping them play an active role in their care, thereby improving treatment outcomes and quality of life.
Collapse
Affiliation(s)
- J-P Lang
- Pôle de psychiatrie, santé mentale et d'addictologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Université de Strasbourg, 67000 Strasbourg, France; Les Toises-centre de psychiatrie et psychothérapie, 1005 Lausanne, Suisse.
| | - N Jurado
- Université de Strasbourg, 67000 Strasbourg, France
| | - C Herdt
- Directrice de la Plate-Forme ETP Alsace, 67000 Strasbourg, France
| | - F Sauvanaud
- Pôle de psychiatrie, santé mentale et d'addictologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France
| | - L Lalanne Tongio
- Pôle de psychiatrie, santé mentale et d'addictologie, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France; Inserm 1114, clinique psychiatrique, hôpitaux universitaires de Strasbourg, 67000 Strasbourg, France
| |
Collapse
|